[Anti-angiogenic drugs].
Angiogenesis or neovascularization, the formation of neo-vessels, is a physiological phenomenon endued in vasculature, but is involved in various pathological conditions. Angiogenesis is required for tumor growth and metastasis, and thus constitutes an important target for the control of tumor progression. Indeed, the recent development of bevacizumab, a neutralizing anti-VEGF monoclonal antibody as the first anti-angiogenic drug, legalized the clinical merit of anti-angiogenesis in cancers. Thereafter, various drugs targeting VEGF-mediated signals have been developed to control tumor angiogenesis. Thus, anti-angiogenic drugs are now recognized in the clinic as a major step forward for the treatment of cancers. This review focuses on the current status of antiangiogenesis treatment in cancers.
Sato
Yasufumi
Y
Department of Vascular Biology, Institute of Development, Aging and Cancer, Tohoku University.
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001557:Benzenesulfonates; D000068258:Bevacizumab; D051793:Hypoxia-Inducible Factor 1; D007211:Indoles; D047908:Intracellular Signaling Peptides and Proteins; D009369:Neoplasms / Q000098:blood supply* / Q000188:drug therapy*; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D017346:Protein Serine-Threonine Kinases; D011725:Pyridines; D011758:Pyrroles; D015398:Signal Transduction; D000077157:Sorafenib; D000077210:Sunitinib; D058570:TOR Serine-Threonine Kinases; D042461:Vascular Endothelial Growth Factor A / Q000276:immunology; D040301:Vascular Endothelial Growth Factor Receptor-2
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D001557:Benzenesulfonates; D051793:Hypoxia-Inducible Factor 1; D007211:Indoles; D047908:Intracellular Signaling Peptides and Proteins; D010671:Phenylurea Compounds; D011725:Pyridines; D011758:Pyrroles; D042461:Vascular Endothelial Growth Factor A; D009536:Niacinamide; D000068258:Bevacizumab; D000077157:Sorafenib; D040301:Vascular Endothelial Growth Factor Receptor-2; D017346:Protein Serine-Threonine Kinases; D058570:TOR Serine-Threonine Kinases; D000077210:Sunitinib